

**RAJEN U. DESAI, MD, FACS**  
CURRICULUM VITAE

**WORK ADDRESSES:** Precision Eye Partners  
385 State Route 18, Suite H, East Brunswick, NJ 08816  
Phone: (732) 698-9300  
Mobile: (650) 283-5712  
E-mail: rudesai@gmail.com

**EDUCATION**

**Undergraduate** Stanford University, Stanford, CA  
9/1998—6/2002 Bachelor of Science, with Honors and Distinction, Biological Sciences

**Medical School** Stanford University School of Medicine, Stanford, CA  
8/2003—6/2008 Doctor of Medicine, with Concentration in Clinical Research

**Internship** Maimonides Medical Center, Brooklyn, NY  
7/2008 — 6/2009 Department of Surgery

**Fellowship** State University of New York Downstate Medical Center, Brooklyn, NY  
7/2009 — 6/2010 Ophthalmology

**Residency** Northwestern University Feinberg School of Medicine, Chicago, IL  
7/2010—6/2013 Ophthalmology

**Fellowship** Northwestern University Feinberg School of Medicine, Chicago, IL  
7/2013—7/2014 Glaucoma Heed Foundation Fellowship

## **PROFESSIONAL ACTIVITIES**

### **Clinical Trials**

- 2025- present      iTrack Global Data Registry: Prospective, Multicenter, Non-Interventional Study of Canaloplasty for Glaucoma (Sponsor: Nova Eye)
- 2024 – present      Principal Investigator, An Observational Registry Study of Safety and Effectiveness Outcomes Through 24 Months Post-operative Following CycloPen System Procedures in Patient with Open Angle Glaucoma: the CREST Registry (Sponsor: Iantrek)
- 2024 – 2025      Principal Investigator, A Prospective, Multi-Center, Single Arm, Non-Comparative, 24-Month Follow Up, Clinical Trial to Study the Safety and Efficacy of MicroPulse Technology for Transscleral Laser Therapy (TLT) as a Standalone Intervention in Pseudophakic Patients with Mild to Moderate Primary Open-Angle Glaucoma: RUNWAY Study. (Sponsor: Iridex)
- 2020 – 2021      Principal Investigator, Outcomes of Ab-Externo XEN 45 Placement – A New Delivery – in Patients with Glaucoma: EXPAND Study. (Sponsor: Allergan)
- 2007 – 2010      Study Co-Chair, Stanford Medical School, Evaluation of Safety and Efficacy of Ranibizumab in Glaucoma Patients with Filtration Tubes. (Sponsor: Genentech)

### **National Medical Advisory Boards**

- 2024 – present      Interventional Glaucoma Working Group, Glaukos
- 2022 – present      Bausch & Lomb
- 2022 – present      Abbvie

### **Work History and Hospital Affiliations**

- 2014 – 2017      Ophthalmologist, AdvantageCare Physicians, New York, NY
- 2014 – 2017      Attending Surgeon, Brook Plaza Ambulatory Surgery Center, Brooklyn, NY
- 2015 – 2016      Attending Physician, The Brooklyn Hospital Center, Brooklyn, NY
- 2017 – 2017      Assistant Attending, Manhattan Eye Ear & Throat Hospital, New York, NY
- 2017 – 2020      Attending Physician, CentraState Medical Center, Freehold, NJ
- 2017 – 2020      Attending Physician, Ocean Medical Center, Hackensack Meridian, Brick, NJ
- 2017 – present      Glaucoma Specialist, Witlin Center for Advanced Eye Care, East Brunswick, NJ
- 2017 – present      Glaucoma Specialist, Santamaria Eye Center, Edison, NJ
- 2017 – present      Glaucoma Specialist, Freehold Ophthalmology, Freehold, NJ
- 2020 – present      Attending Physician, Raritan Bay Medical Center, Perth Amboy, NJ

### **Institutional Service**

2019 – 2020 Pharmacy & Therapeutics Committee, CentraState Medical Center  
2011 – 2012 Executive Committee, Department of Ophthalmology, Northwestern University  
2006 – 2008 Admissions Committee, Stanford School of Medicine

### **Teaching**

2013 – 2014 Instructor in Ophthalmology, Northwestern Univ. Feinberg School of Medicine  
2005 – 2009 Medical student tutor, Center of Excellence, Stanford School of Medicine  
2005 – 2008 Medical student tutor, Office of Accessible Education, Stanford University

### **Extramural Leadership**

2024 – present Member, Board of Directors, Precision Foundation for Sight  
2004 – 2005 Co-President, Physicians for Social Responsibility, Stanford School of Medicine  
2004 – 2005 Co-President, Physicians for Human Rights, Stanford School of Medicine  
2001 – 2002 Co-President, Stanford South Asian Society  
1999 – 2000 Co-President, Stanford CRP Instructors, Stanford University  
1993 – 1998 2<sup>nd</sup> Lieutenant, United States Air Force Auxiliary, Civil Air Patrol

### **LICENSURE & CERTIFICATION**

American Board of Ophthalmology, expires 2034  
New Jersey medical licensure

### **PROFESSIONAL MEMBERSHIPS**

American Academy of Ophthalmology  
American Glaucoma Society  
American Society of Cataract and Refractive Surgery  
American College of Surgeons  
Society of Heed Fellows  
New Jersey Ophthalmology Society

### **COMMERCIAL RELATIONSHIPS**

Abbvie: consultant, speaker, research funding  
Alcon: consultant, speaker  
Bausch & Lomb: consultant, speaker  
Beaver-Visitec International: consultant, speaker  
Genentech: research funding  
Glaukos: consultant, speaker  
Gore Medical: consultant

Iantrek: consultant, speaker, research funding, stock option  
Iridex: consultant, speaker  
Ivantis: consultant, speaker  
MicroSurgical Technology: consultant, speaker  
New World Medical: consultant, speaker  
Nova Medical: consultant, speaker, research funding  
Ocular Therapeutix: consultant, speaker  
Rayner: consultant, speaker  
Sight Sciences: consultant, speaker  
Sun Pharmaceuticals: consultant, speaker

## GRANT AWARDS

2013 \$10,000: Heed Ophthalmic Foundation, Society of Heed Fellows  
2011 \$3,390: Knights Templar Eye Foundation, Inc.  
2008 \$94,000: Genentech, Inc.  
2005 \$48,000: Stanford Medical Scholar Fund  
2001 \$10,000: Stanford Vice Provost Undergraduate Education  
2000 \$2,200: Howard Hughes Undergraduate Fellowship  
1999 \$5,000: Stanford President's Scholar Fund

## HONORS

2013 **Society of Heed Fellows Award** (1 of 5 fellows selected nationally)  
2013 **Heed Ophthalmic Foundation Fellow** (1 of 20 fellows selected nationally)  
2013 **Chief Resident**, Northwestern University Feinberg School of Medicine, Chicago, IL  
2012 **Academic Achievement Award**, Dept. Ophthalmology, Northwestern University Feinberg School of Medicine (for highest OKAP score)  
2012 **Best Resident Teacher of Medical Students**, Dept. Ophthalmology, Northwestern University Feinberg School of Medicine  
2012 **Distinguished Poster**. 2012 North American Neuro-Ophthalmology Society Annual Meeting, "Why Mothers Say 'Look At Me When I'm Talking To You': The Effect of Amblyopia on Visual-Auditory Speech Perception"

- 2011      **Best Resident Teacher of Medical Students**, Dept. Ophthalmology, Northwestern University Feinberg School of Medicine
- 2009      **Intern of the Year**, Dept. Surgery - Transitional, Maimonides Medical Center
- 2002      **Phi Beta Kappa**, Stanford University
- 2002      **Stanford University Dean of Students Outstanding Achievement Award**
- 2002      **Stanford University Asian American Alumni Distinguished Student Award**
- 2002      **National Semi-Finalist**, Innovation in Health Promotion, United States Department of Health & Human Services
- 1998      **National Mitchell Award**, United States Air Force Civil Air Patrol
- 1997      **Solo Pilot of the Cessna 172 aircraft**, United States Air Force Civil Air Patrol

## **INVITED LECTURES**

1. *Why Practices Need to Adapt to the Interventional Glaucoma Mindset*. March 25, 2026. Webinar. (sponsored by Glaukos)
2. *Surgical Success in Performing the AlloFlo Implantation*. March 5, 2026. (sponsored by Iantrek)
3. *iDose - Secrets for Surgical Success*. February 19, 2026. Redding, PA. (sponsored by Glaukos)
4. *Pearls to Optimize Safety in Canaloplasty*. January 29, 2026. Webinar. (sponsored by Nova Eye)
5. *Optimizing the Ocular Surface for Premium Cataract Surgery*. January 27, 2026. Albany, NY. (sponsored by Sun Pharma)
6. *Leveraging OR Turnover Time into Opportunity: Offsetting the Economics of Cataract Surgery with Transscleral Cyclophotocoagulation using MicroPulse Technology*. January 20, 2026. Webinar. (sponsored by Iridex)
7. *Can Ozempic Make Me Blind? Oral medication and vision loss*. January 8, 2026. Iselin, NJ (COPE credited course)
8. *Durysta Now – Innovation for Impact*. November 18, 2025. Annapolis, MD (sponsored by Abbvie)

9. *Understanding Optics for Aspire Toric and Envy IOLs*. November 6, 2025. Albany, NY. (sponsored by Bausch & Lomb)
10. *Rethinking Dry Eye*. October 21, 2025. Tarrytown, NY. (sponsored by Bausch & Lomb)
11. *Patient Selection and Surgical Pearls for the AlloFlo*. October 18, 2025. (sponsored by Iantrek)
12. *Rethinking Dry Eye*. October 15, 2025. Newton, PA (sponsored by Bausch & Lomb)
13. *Cequa*. October 8, 2025. Lincroft, NJ. (sponsored by Sun Pharma)
14. *A Branded First-line Treatment, From the Start*. September 30, 2025. Toms River, NJ. (sponsored by Bausch & Lomb)
15. *iDose: What Does the Patient Conversation Sound Like?* September 25, 2025. Webinar. (sponsored by Glaukos)
16. *Rethinking Dry Eye*. September 24, 2025. Summit, NJ (sponsored by Bausch & Lomb)
17. *Durysta Now – Innovation for Impact*. September 23, 2025. Pittston, PA (sponsored by Abbvie)
18. *Rethinking Dry Eye*. September 17, 2025. Edison, NJ (sponsored by Bausch & Lomb)
19. *Hydrus microstent*. September 9, 2025. Jersey City, NJ (sponsored by Alcon)
20. *Durysta Now – Innovation for Impact*. September 2, 2025. Cherry Hill, NJ. (sponsored by Abbvie)
21. *Optimizing Outcomes with Aspire, IC-8 Aphaera, and Envy IOLs*. August 14, 2025. Newburgh, NY. (sponsored by Bausch & Lomb)
22. *Interventional Glaucoma Innovations*. June 19, 2025. Providence, RI. (sponsored by Glaukos)
23. *A Branded First-line Treatment, From the Start*. June 5, 2025. Williamsville, NY. (sponsored by Bausch & Lomb)
24. *Surgical pearls for implanting iDose*. May 22, 2025. Boston MA. (sponsored by Glaukos)
25. *Patient selection for implanting iStent Infinite and iDose*. May 21, 2025. Bethlehem, PA. (sponsored by Glaukos)
26. *The Catalysts to Advance the Interventional Glaucoma Revolution*. May 15, 2025. East Brunswick, NJ. (sponsored by Glaukos)

27. *Rethinking Dry Eye*. Mary 15, 2025. Somerville, MD. (sponsored by Bausch & Lomb)
28. *Rethinking Dry Eye*. Mary 13, 2025. Townson, MD. (sponsored by Bausch & Lomb)
29. *Cannabis for Glaucoma?* March 20, 2025. Edison, NJ. (COPE credited course)
30. *Evolved LRIs: Safer, Simpler, Sharper Vision*. January 28, 2025. Webinar (sponsored by MicroSurgical Technology)
31. *Nutrition and Diet Updates for Glaucoma*. January 12, 2025. Somerset, NJ. (COPE credited course)
32. *Rethinking Dry Eye Disease*. December 10, 2024. Millburn, NJ. (sponsored by Bausch & Lomb)
33. *Rethinking Dry Eye Disease*. November 21, 2024. Atlantic City, NJ. (sponsored by Bausch & Lomb)
34. *A Branded First-line Treatment, From the Start*. November 13, 2024. Queens, NY. (sponsored by Bausch & Lomb)
35. *Durysta Now – Innovation for Impact*. November 11, 2024. Westfield, NJ. (sponsored by Allergan)
36. *Initial Experience with the Envy IOL*. November 7, 2024. New York Intraocular Lens Society Meeting, New York, NJ. (sponsored by Bausch & Lomb)
37. *Rethinking Dry Eye Disease*. November 6, 2024. Marlboro, NJ. (sponsored by Bausch & Lomb)
38. *Omni Surgical System Goniotomy Pearls*. October 29, 2024. Red Bank, NJ. (sponsored by Sight Sciences)
39. *Rethinking Dry Eye Disease*. October 23, 2024. Red Bank, NJ. (sponsored by Bausch & Lomb)
40. *ArcDuo Limbal Relaxing Incisions: When Blades are Inaccurate and Femto is Costly*. October 19, 2024. American Academy of Ophthalmology Annual Meeting. (sponsored by MicroSurgical Technology)
41. *Rethinking Dry Eye Disease*. October 10, 2024. Westfield, NJ. (sponsored by Bausch & Lomb)
42. *Mental Health Medications that Can Increase the Risk of Glaucoma*. October 8, 2024. Edison, NJ. (COPE certified CE course).

43. *Rethinking Dry Eye Disease*. September 26, 2024. Red Bank, NJ. (sponsored by Bausch & Lomb)
44. *A Branded First-line Treatment, From the Start*. September 25, 2024. Forrest Hills, NY. (sponsored by Bausch & Lomb)
45. *Durysta Now – Innovation for Impact*. September 18, 2024. Webinar. (sponsored by Allergan)
46. *Elevate Your Every Day with Envista Aspire IOLs*. September 17, 2024. New Brunswick. (sponsored by Bausch & Lomb)
47. *Rethinking Dry Eye Disease*. August 29, 2024. Tom’s River, NJ. (sponsored by Bausch & Lomb)
48. *Omni Surgical System Canaloplasty Pearls*. July 24, 2024. Red Bank, NJ. (sponsored by Sight Sciences)
49. *Algorithm in Deciding Minimally Invasive Glaucoma Surgery*. May 19, 2024. Somerset, NJ. (COPE certified CE course).
50. *iDose implantation technique: step-by-step*. May 2, 2024. Corporate training video (sponsored by Glaukos)
51. *Glaucoma Patients: Benefits of RayOne EMV - Peer2Peer Ben LaHood with Rajen Desai*. April 25, 2024. (Rayner YouTube channel)
52. *Elevate Your Every Day with Envista Aspire IOLs*. April 18, 2024. New Brunswick. (sponsored by Bausch & Lomb)
53. *Pearls of implanting iDose and iStent Infinite*. April 16, 2024. New Jersey Glaucoma Society Meeting. Princeton, NJ (sponsored by Glaukos)
54. *Ahmed ClearPath 250 implantation: technique pearls*. March 15, 2024 (surgical training video, sponsored by New World Medical)
55. *Mini-monovision using RayOne EMV*. February 28, 2024. Toronto, Canada. (sponsored by Rayner)
56. *RayOne EMV vs Vivify: How to Deliver the Best Patient Outcomes*. February 14, 2024. Webinar (Rayner YouTube channel)
57. *Enhanced Monofocal IOLs for Skeptical Cataract Surgeons*. January 17, 2024. Phoenix, AZ (sponsored by Rayner)

58. *Upgrading keratome and IOL choices for skeptical surgeons*. July 10, 2023. National sales meeting webinar. (sponsored by Beaver-Visitec International)
59. *RayOne vs Vivity in Glaucoma*. American Academy of Ophthalmology Annual Meeting. November 4, 2023. San Francisco, CA (sponsored by Rayner)
60. *How Blood Pressure Medications Affect Glaucoma*. October 3, 2023. Edison, NJ. (COPE certified CE course)
61. *Glaucoma Cases, Simplified Goniotomy*. December 2, 2022. Surgical video (sponsored by MicroSurgical Technology)
62. *Why I've Incorporated IPure into my Practice*. November 29, 2022. Webinar (sponsored by Beaver-Visitec International)
63. *Pregnancy and Ocular Medications*. November 13, 2022. Edison, NJ (COPE certified CE course)
64. *Durysta Now – Innovation for Impact*. September 22, 2022. Nyack, NY. (sponsored by Allergan)
65. *Hydroxychloroquine Maculopathy*. November 9, 2021. (COPE certified CE course). Edison, NJ
66. *The next generation of presbyopia-correcting IOLs: Eyhance, Synergy, PanOptix, and Vivity*. September 21, 2021. (COPE certified CE course). Woodbridge, NJ
67. *Dextenza*. July 29, 2021. New York, NY (sponsored by Ocular Therapeutix)
68. *Micropulse Trans-scleral Laser Therapy in Combination with Other Glaucoma Treatments*: July 15, 2021. Webinar. (sponsored by Iridex)
69. *Hydrus Microstent*. Edison, NJ. June 17, 2021. (sponsored by Ivantis)
70. *Vyzulta*. June 3, 2021. Webinar. (sponsored by Bausch & Lomb)
71. *Micropulse Trans-scleral Laser Therapy*. June 17, 2020. Webinar. (sponsored by Iridex)
72. *Omni Surgical System: Mastering the Learning Curve*. May 14, 2020. Webinar. (sponsored by Sight Sciences Inc.)
73. *Droplless steroid and ocular hypotensive medications*. January 12, 2020. (COPE certified CE course), Somerset, NJ

74. *Oral Antibacterial Medications and Oral Glaucoma Medications*. November 11, 2019. (COPE certified CE course). Edison, NJ
75. *Cannabis and supplements for glaucoma*. June 19, 2019. (COPE certified CE course.) Edison, NJ.
76. *Does marijuana work for glaucoma?* June 12, 2019. (COPE certified CE course.) Morristown, NJ.
77. *Co-Managing Cataract and Minimally Invasive Glaucoma Surgery*. (COPE certified CE course.) February 17, 2019. Piscataway, NJ.
78. *Disease Progression: Emerging Trends and Strategies in Glaucoma Management*. December 6, 2018. Edison, NJ. (sponsored by Allergan)
79. *Applying Rho-kinase inhibitors into glaucoma management*. (COPE certified CE course.) November 7, 2018. Tom's River, NJ
80. *Second generation MIGS*. (COPE certified CE course.) November 13, 2018. New Brunswick, NJ
81. *Practice patterns in glaucoma pharmaceutical sales*. October 9, 2018. New York, NJ (Presentation to Allergan managers of sales and marketing.)
82. *Controversies in Glaucoma Management Panel: Do I send this patient to an optometrist to manage?* American Glaucoma Society Annual Meeting. March 3, 2018. New York, NY
83. *The Science and Art of Setting a Target IOP*. (COPE certified CE course.) Piscataway. February 11, 2018.
84. *When POAG was the wrong diagnosis*. (COPE certified CE course.) November, 21, 2017. Tom's River, NJ.
85. *When glaucoma was the wrong diagnosis*. (COPE certified CE course.) November, 14, 2017. Edison, NJ.
86. *Initial Experience with iStent at Northwestern: IOP Control versus Anterior Segment OCT of Schlemm's Canal Positioning*. 2014 Northwestern University Vision Research Day Symposium. Chicago, IL
87. *Amblyopia, Autism, and Audio-Visual Integration*. 2013 Northwestern University Vision Research Day Symposium. Chicago, IL
88. *Sensitivity and Specificity of Frequency Doubling Perimetry With the Humphrey Matrix in the Detection of Homonymous Visual Field Defects*. 2010 Annual Meeting of the American Academy of Ophthalmology, Chicago, IL

89. *Long-term Results of the Artisan Phakic Intraocular Lens for the Correction of Severe Hyperopia in the United States: A Prospective Multi-Center Study*. 2008 Annual Symposium of the American Society of Cataract and Refractive Surgeons, Chicago, IL

## PEER-REVIEWED PUBLICATIONS

1. Verma R, **Desai RU**. Angle Neighbors– Endoscopic View of iDose and iStent. *Ophthalm Glaucoma* (submitted)
2. Shah, M; Syal S, **Desai RU**, Khouri AS. Hyphema and Vitreous Hemorrhage after Micropulse Cyclophotocoagulation a Case Report. *Euro J Ophthalmol*. 2024 Jul;34(4):NP16-NP19
3. Mobile bimatoprost implant requiring surgical extraction. Yakobashvili D, Oydanich M, **Desai RU**, Khouri AS. *J Fr Ophtalmol*. 2024 Nov;47(9):104287
4. Shah YS, Oydanich M, **Desai RU**, Chinskey N, Khouri AS. Appositional Choroidal Detachment Following XEN45 Gel Stent Requiring Surgical Drainage. *J Glaucoma*. 2021 Nov 12.
5. Burgmeier R, **Desai RU**, Farner K, Tiano B, Lacey R, Volpe NJ, Mets MB. The Effect of Amblyopia on Visual-Auditory Speech Perception: Why Mothers May Say ‘Look At Me When I’m Talking To You’. *JAMA Ophthalmol*. 2015 Jan;133(1):11-6
6. Tanna AP, **Desai RU**. Evaluation of Visual Field Progression in Glaucoma. *Curr Ophthalmol Rep*. 2014;2:75–79
7. Sohrab MA, **Desai RU**, Chambers CB, Lissner GS. Drug-Induced Graves’ Disease from CTLA-4 Receptor Suppression. *Ophthalm Plast Reconstr Surg*. 2013 May-Jun;29(3):239-40
8. **Desai RU**, Singh K, Lin SC. Intravitreal Ranibizumab as an Adjunct for Ahmed Valve Surgery in Open Angle Glaucoma: A Pilot Study. *Clin & Exp Ophthalmol*. 2013 Mar;41(2):155-8.
9. Saffra, NA, **Desai RU**, Har-zvi N. Pediatric amblyopia screening. *Ophthalmology*. 2011 Jun;118(6):1222-3
10. Saffra NA, Perlman JE, **Desai RU**, Kazacos KR, Coyle CM, Machado FS, Kedhar SR, Engelbert M, Tanowitz HB. *Baylisascaris procyonis* induced diffuse unilateral subacute neuroretinitis in New York City. *J Neuroparasitology*. 2010 Jan 1;15-8
11. Saffra NA, **Desai RU**, Seidman CJ, Chapnick EK. Endogenous fungal endophthalmitis after cardiac surgery. *Ophthalmic Surg Lasers Imaging*. 2010 Oct 28;41:e1-3

12. Shaw J, Smith EF, **Desai RU**, Enriquez BM, Schrier A. Can Intraocular Lenses Deliver Antibiotics Intracamerally? *J Ocul Pharmacol Ther.* 2010 Dec;26(6):587-9
13. Smith EF, **Desai RU**, Schrier A, Enriquez B, Purewal BK. Trypan Blue Capsulorrhexis. *Ophthalmology.* 2010 Jul;117(7):1462-1462.e1
14. Sharma S, **Desai RU**, Pass AB, Saffra NA. Vancomycin Resistant Enterococcus Endophthalmitis. *Arch Ophthalmol.* 2010 Jun;128(6):794-5
15. **Desai RU**, Saffra NA, Krishna RP, Rosenberg SR. Coats' disease, Turner Syndrome, and von Willebrand disease in a patient with wildtype Norrie Disease Pseudoglioma. *J Pediatr Ophthalmol Strabismus.* 2010 Mar 26:1-3
16. **Desai RU**, Pekmezci M, Tam D, Song J, Lin SC. Resident-Performed Primary Ahmed Valve Surgery. *Ophthalmic Surg Lasers Imaging.* 2010 Mar-Apr;41(2):222-7
17. Perlman JE, Kazacos KR, Imperator GH, **Desai RU**, Schulman SK, Edwards J, Ponrelli LR, Tanowitz HB, Saffra NA. *Baylisascaris procyonis* neural larva migrans in an infant in New York City. *J Neuroparasitology.* 2010;1:1-5
18. **Desai RU** and Saffra NA. Argon laser photocoagulation of a vitreous cyst. *Ophthalmic Surg Lasers Imaging.* 2010 Mar 9:1-4
19. **Desai RU**, Rachakonda LP, Saffra NA. Trichomegaly secondary to erlotinib. *Can J Ophthalmol.* 2009. Dec;44(6):e65.
20. Jain A, **Desai RU**, Charalel R, Yannuzzi L, Sarraf D. Chronic Solar Retinopathy: Comparison of Optical Coherence Tomography and Fluorescein Angiography. *Retina.* 2009. Oct;29(9):1340-5.
21. Jain A, **Desai RU**, Jain R, Rachakonda L. *Streptococcus Bovis* Causing Perforating Corneal Ulcer. *Cornea.* 2009 Jan;28(1):120-1.
22. Wong LJ, **Desai RU**, Feliciano D, Jain A, Moshfeghi DM, Sanislo SR, Blumenkranz MS. Surveillance for Potential Adverse Events Associated with the Use of Intravitreal Bevacizumab for Retinal and Choroidal Vascular Disease. *Retina.* 2008 Oct;28(8):1151-8.
23. **Desai RU**, Jain A, Manche EE. Long-term Evaluation of Hyperopic Laser in situ Keratomileusis Using the S2 Excimer Laser. *J Cataract Refract Surg* 2008 Feb;34(2):232-7
24. Jain A, **Desai RU**, Ehrlich J. Fulminant Orbital Myiasis in the Developed World. *Br J Ophthalmol.* 2007 Nov; 91(11):1565-6.

## OTHER PUBLICATIONS

1. Desai RU. *Leveraging OR Turnover Time into Opportunity: Offsetting the Economics of Cataract Surgery with Transscleral Cyclophotocoagulation using MicroPulse Technology* (Iridex white paper, in press)
2. Francis BA, Vera V, Kim J, et al. One-Year Real-World Outcomes of Ab-Externo Gel Stent Placement From the EXPAND Study. *J Glaucoma*. 2025 Apr 1;34(4):330-341. (Acknowledged as principal investigator)
3. Funke CM, Ristvedt D, Yadgarov A, et al. Interventional glaucoma consensus treatment protocol, *Expert Review of Ophthalmology*, 2025: 20:2, 79-87 (Acknowledged as a member of the Interventional Glaucoma Working Group)
4. **Desai RU**. Managing Refractory Glaucoma: A Case Study in Stent-based MIGS. *Glaucoma Today*. Fall 2025 (sponsored by Glaukos)
5. Dynamic Collaborations Between Optometrists and Ophthalmologists. *Cookie Optometry*. March 2025 (featured interview)
6. **Desai RU**. “Hyphema Management, Simplified: Minimizing the Impact of Hyphema in Goniectomy Procedures.” *Ophthalmology Times Europe*. December 2022
7. **Desai RU**. “Rediscovering the goniotomy option.” *Ophthalmology Times*. July/August 2018.
8. **Desai RU**. “Co-managing glaucoma: One MD’s Experience.” *Review of Ophthalmol*. June 2018.
9. **Desai RU**, Grewal DS, Sohrab MA, Pyatetsky D. “Journal Club Review: Corneal endothelial damage after cataract surgery in eyes with pseudoexfoliation syndrome.” *EyeWorld*. June 2013

## POSTERS

1. Oydanich M, Skula S, Yakobashvili D, Verma R, **Desai RU**, Khouri AS. Comparison of the Effectiveness of the Ahmed Glaucoma Valve and the Ahmed ClearPath in Intraocular Pressure Reduction. American Glaucoma Society 2025 Annual Meeting.
2. Oydanich. M, Yakobashvili D, Skula S, **Desai RU**, Khouri AS. Efficacy of Ahmed ClearPath in Lowering Intraocular Pressure In Primary & Secondary Forms of Glaucoma. 2024 Association for Research in Vision and Ophthalmology Annual Meeting. Seattle, WA.

3. Yakobashvili D, Oydanich M, **Desai RU**, Khouri AS. The Dancing Implant: A Case of a Mobile Bimatoprost Implant Requiring Surgical Extraction. 2024 Rutgers Medical School Research Symposium.
4. **Desai RU**, Burgmeier R, Kiesau Y, Rahmani B, Yoon H, Zeid JL, Volpe NJ, Mets MB. "The Effect of Amblyopia on Visual-Auditory Speech Perception." 2012 Annual Meeting of the American Academy of Ophthalmology. Chicago, IL
5. **Desai RU**, Singh K, Lin SC. Intravitreal Ranibizumab as an Adjunct for Ahmed Valve Surgery in Open Angle Glaucoma: A Pilot Study. 2012 Annual Meeting of the Association for Research in Vision and Ophthalmology. Fort Lauderdale, FL
6. **Desai RU**, Burgmeier R, Volpe NJ, Mets MB. "The Effect of Amblyopia on Visual-Auditory Speech Perception." 2012 Northwestern University Feinberg School of Medicine Annual Lewis Landsberg Research Day. Chicago, IL
7. **Desai RU**, Burgmeier R, Volpe NJ, Mets MB. "Why Mothers May Say 'Look At Me When I'm Talking To You': The Effect of Amblyopia on Visual-Auditory Speech Perception." 2012 North American Neuro-Ophthalmology Society Annual Meeting. San Antonio, TX
8. **Desai RU**, Schrier A, Berg PD, Smith EF. Sensitivity and Specificity of Frequency Doubling Perimetry With the Humphrey Matrix in the Detection of Homonymous Visual Field Defects. 2011 Annual Meeting of the Assoc. for Research in Vision and Ophthalmology. Fort Lauderdale, FL
9. Liu M, Burstein E, **Desai RU**, Bhandari R, Enriquez B, Smith E, Lazzaro DR. The Effect of Trypan Blue on Endophthalmitis Pathogens in Vitro. 2010 Annual Meeting of the American Academy of Ophthalmology. Chicago, IL
10. Wong LJ, **Desai RU**. IOP and Intravitreal Bevacizumab Injections. 2010 Annual Meeting of the American Academy of Ophthalmology. Chicago, IL
11. **Desai RU**, Lin SC. Intravitreal Ranibizumab Efficacy as an Adjunctive Therapy for Ahmed Valve Surgery: Randomized Clinical Trial. 2010 Annual Meeting of the Association for Research in Vision and Ophthalmology. Fort Lauderdale, FL
12. Liu M, **Desai RU**, Enriquez B, Smith EF. A Comparison of the Accuracy and Efficiency of an Innovative Ultrasound Device With Routine A Scan Biometry in a Resident Clinic Setting. 2010 Annual Meeting of the Assoc. for Research in Vision and Ophthalmology. Fort Lauderdale, FL
13. Ching K, Feldman M, **Desai RU**, Fogel J, Borgen P, Andaz C. "Breast Specific Gamma Imaging: Integration into surgical practice." 2009 Annual Meeting of the American Society of Breast Surgeons. San Diego, CA

14. **Desai RU**, Charalel R, Jain A, Feliciano D, Moshfeghi DM, Sanislo SR, Blumenkranz MS, Vollrath D. Exudative Age-Related Macular Degeneration Treatment Response to Intravitreal Bevacizumab, Ranibizumab, and Photodynamic Therapy Associated with Complement Factor H and LOC387715 Genotypes. 2009 Annual Meeting of the Association for Research in Vision and Ophthalmology. Fort Lauderdale, FL
15. Lin SC and **Desai RU**. Efficacy and Safety of Intravitreal Ranibizumab as an Adjunctive Therapy for Ahmed Valve Surgery. 2009 Annual Meeting of the Association for Research in Vision and Ophthalmology. Fort Lauderdale, FL
16. Wong LJ, **Desai RU**, Jain A, Moshfeghi DM, Sanislo SR, Blumenkranz MS. Surveillance for Potential Adverse Events Associated with the Use of Intravitreal Bevacizumab for Retinal and Choroidal Vascular Disease. 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology. Fort Lauderdale, FL
17. **Desai RU**, Jain A, Manche EE. Long-term Results of the Artisan Phakic Intraocular Lens for the Correction of Severe Hyperopia in the United States: Prospective Multi-Center Study. 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology. Fort Lauderdale, FL
18. **Desai RU**, Jain A, Manche EE. Long-term evaluation of hyperopic LASIK using the Visx S2 Excimer Laser. 2007 Annual Meeting of the Association for Research in Vision and Ophthalmology. Fort Lauderdale, FL
19. Jain A, **Desai RU**, Manche EE. Long-term evaluation of hyperopic laser in situ keratomileusis using the Visx S2 Excimer Laser. 2007 American Society of Cataract and Refractive Surgeons Symposium. Chicago, IL